BRD4 and hepatocellular carcinoma: In this iteration of SSO‐QPOP, we selected four SSOs against MYC synthetic lethal targets (CHEK1, MAX, MCL1, and BRD4) with the greatest knockdown efficiencies amongst a panel of eight targets, together with two HCC standard‐of‐care drugs, sorafenib and cabozantinib to compare the efficacy of targeting MYC synthetic lethality with the standard‐of‐care drugs.65, 66